echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Pfizer meets its rivals again!

    Pfizer meets its rivals again!

    • Last Update: 2021-08-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    A few days ago, Shisiyao Group issued an announcement that Shijiazhuang Siyao's linezolid glucose injection was approved for production in imitation category 4, and it was deemed to have been reviewed


    Linezolid, developed by Pfizer, is a synthetic oxazolidinone antibiotic, mainly used to treat infections caused by Gram-positive bacteria that are resistant to other antibiotics


    Sales of terminal linezolid glucose injection in public medical institutions in China in recent years (unit: 100 million yuan)

    Source: Terminal competition landscape of China's public medical institutions

    According to data from Minai.


    Source: Meinenet MED2.


    In terms of consistency evaluation, linezolid glucose injection has been evaluated by 5 companies.


    Source: Listed company announcements, Mi Nei.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.